Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US market ...
The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after positive ...
If you would like more information about your grant application, please contact the Community Recovery Hotline on 1800 173 349. you either live in or are stranded in an eligible area affected by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback